HK Stock Market Move | XTALPI (02228) rises over 7%; Chairman plans to increase shareholding in the company; enters drug discovery collaboration with Stanford University.

XTALPI (02228) rose over 7%, after surging more than 16% in the previous trading session. As of press time, it was up 7.61% at HK$8.63, with a turnover of HK$922 million. On the news front, XTALPI announced that the company's board of directors has been informed that Dr. Wen Shuhao, Chairman of the Board, Executive Director and Co-founder of the company, based on his confidence in the group's future development prospects and recognition of the company's long-term investment value, intends to increase his shareholding in the company's ordinary shares in the open market with his own funds before the end of October 2026. According to the shareholding increase plan, Dr. Wen Shuhao intends to increase his shareholding at a total consideration not exceeding HK$32 million. It is worth noting that XTALPI recently announced that its wholly-owned subsidiary LCC Technologies has entered into a drug discovery collaboration agreement with Stanford University. The two parties will combine Stanford University's expertise in disease biology research with LCC's small molecule drug discovery platform to jointly evaluate new biological discoveries and explore their potential for further development into small molecule therapeutic drugs. Under the agreement, LCC will work with Stanford University researchers to advance promising research projects and accelerate the progression of related discoveries toward the drug development stage.